TICKERNERD
Menu
BRTXBRTXHealthcare · Biotechnology

BRTX Stock Forecast: BioRestorative Therapies, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$2.70

The 2 Wall Street analysts covering BioRestorative Therapies, Inc. hold a median 12-month price target of $160 — +5825.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.7M
Ticker Nerd rank
8 / 100
Median analyst target
$160
Analysts covering
2
Revenue$23K−7.3% y/y
Operating income−$3.4M
Net income−$2.2M
Free cash flow−$3.8M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

BRTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioRestorative Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
39
Growth
30
Revisions
26
Momentum
19
Value
17
Issuance
14
Volatility
7
Quality
7

Size (97): Smaller than most of the companies we track.

Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BRTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BRTX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $20Median $160High $300

The green dot is the last close — the median target sits +5825.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2024Roth MKMMaintainsBuy$15 → $18
12 June 2024Roth MKMMaintainsBuy—
14 Aug 2023Roth MKMReiteratesBuy—
7 Dec 2022Roth CapitalInitiatesBuy—
28 Sept 2022Maxim GroupInitiatesBuy—
1 Dec 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BRTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

BioRestorative Therapies, Inc. (BRTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
10.4×

Cheaper than 14% of US stocks

Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−7.3%

Higher than 18% of US stocks

Earnings growth (YoY)
−7.3%

Higher than 28% of US stocks

Gross margin
68.1%

Higher than 81% of US stocks

Operating margin
−14612.6%

Higher than 1% of US stocks

Net margin
93.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−241.1%

Higher than 6% of US stocks

Return on assets
−118.8%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioRestorative Therapies, Inc. (BRTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioRestorative Therapies, Inc. has a market value of $3.7M and an enterprise value of −$124K.

  • Revenue in the twelve months to 31 Mar 2026: $358K. The latest quarter shrank 7.3% year on year.

  • Net income over the same four quarters: −$11.1M, a −3089.6% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$11.9M, after $80K of capital spending.

  • Shares outstanding: 25.5M.

  • Trailing P/E: −1.7×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioRestorative Therapies, Inc. employs 13 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

BRTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BRTXBioRestorative Therapies, Inc.$3.7M
8
REVBRevelation Biosciences, Inc.$3.7M
7
ELABPMGC Holdings, Inc.$3.7M
3
XRTXXORTX Therapeutics, Inc.$3.8M
13
CVKDCadrenal Therapeutics, Inc.$3.8M
34
TCRTAlaunos Therapeutics, Inc.$3.6M
29
MBIOMustang Bio, Inc.$3.9M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioRestorative Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BRTX news & analysis

BioRestorative Therapies Announces Reverse Stock Split

GlobeNewsWire · 2 Sept 2026neutral

BioRestorative Therapies announced that its Board of Directors approved a 1-for-20 reverse stock split of its common stock, effective as of 4:30 p.m. Eastern Time on September 7, 2026. The stock will begin trading on a split-adjusted basis on Nasdaq on September 8, 2026, under the symbol "BRTX" with a new CUSIP number.

Why it matters — The reverse stock split is intended to help BioRestorative Therapies regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing.

FAQ

Frequently asked questions about BRTX stock

What is the BRTX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering BioRestorative Therapies, Inc. have a median 12-month price target of $160, with estimates ranging from $20 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BRTX stock a buy right now?

Of the 2 analysts covering BioRestorative Therapies, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioRestorative Therapies, Inc. 8 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BRTX?

As at 14 Sept 2026, BioRestorative Therapies, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will BRTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +5825.9% from the last close, and Ticker Nerd's factor model ranks BioRestorative Therapies, Inc. 8 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BRTX stock forecast for 2030?

No analyst covering BioRestorative Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $300 over the next 12 months.

What does BioRestorative Therapies, Inc. do?

BioRestorative Therapies Inc. is a biotechnology company focused on developing regenerative medicine products and therapies using cell and tissue protocols, primarily based on adult stem cells.

What is the latest news on BRTX?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "BioRestorative Therapies Announces Reverse Stock Split". BioRestorative Therapies announced that its Board of Directors approved a 1-for-20 reverse stock split of its common stock, effective as of 4:30 p.m. Eastern Time on September 7, 2026. The stock will begin trading on a split-adjusted basis on Nasdaq on September 8, 2026, under the symbol "BRTX" with a new CUSIP number.

Company

About BioRestorative Therapies, Inc.

BioRestorative Therapies Inc. is a biotechnology company focused on developing regenerative medicine products and therapies using cell and tissue protocols, primarily based on adult stem cells. BioRestorative Therapies Inc. centers its current work on two main programs: a disc and spine therapy platform for degenerative disc disease and chronic back pain, and a metabolic disease platform aimed at obesity and related disorders. Its pipeline includes BRTX-100, an autologous cell therapy candidate designed for spinal applications, and ThermoStem, a cell-based program built around brown adipose tissue biology. The company also works with an investigational delivery device for spine and disc treatments and operates a commercial biocosmeceutical platform. Based in Melville, New York, BioRestorative Therapies Inc. participates in the broader biotechnology and regenerative medicine market, where it develops treatment approaches intended to address unmet medical needs in musculoskeletal and metabolic health.

CEO Mr. Lance Alstodt · 13 employees · United States · https://www.biorestorative.com